Shares of Moderna MRNA rose nearly 16% yesterday after a couple of SEC filings showed that two board members bought shares on ...

German biotech major BioNTech (Nasdaq: BNTX) has suffered a blow as it seeks to add new revenue streams beyond its COVID-19 ...

BioNTech (NASDAQ:BNTX – Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Monday, March 10th. Analysts expect the company to announce earnings of $0.38 per ...

In a report released yesterday, Harry Gillis from Berenberg Bank maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price ...

BioNTech's malaria vaccine trial faces an FDA clinical hold. The company is addressing concerns and collaborating with ...

Ugur Sahin, the co-founder and CEO of BioNTech SE (BNTX), sold $119.58 million worth of the Germany-based biotechnology ...

European equities traded in the US as American depositary receipts were tracking lower late Thursday morning, declining 0.61% to 1,444.24 on the S&P Europe Select ADR Index. From continental Europe, ...

The court said Pfizer and BioNTech would have to provide information on earnings derived from the use of the patent and that ...

In this article, we are going to take a look at where BioNTech SE (NASDAQ:BNTX) stands against other best immunology stocks to buy now. Immunology is a rapidly advancing field with significant ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Investors might want to bet on BioNTech SE Sponsored ADR (BNTX), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates ...

The FDA’s clinical hold has prompted a cautious response from investors, reflecting the heightened regulatory scrutiny that BioNTech now faces. The company’s immediate focus will be on resolving the ...